The computational prediction of aqueous solubility and/or human absorption has been the goal of many researchers in recent years. Such an in silico counterpart to the biopharmaceutical classifi cation system (BCS) would have great utility. This review focuses on recent developments in the computational prediction of aqueous solubility, P-glycoprotein transport, and passive absorption. We fi nd that, while great progress has been achieved, models that can reliably affect chemistry and development are still lacking. We briefl y discuss aspects of emerging scientifi c understanding that may lead to breakthroughs in the computational modeling of these properties.
INTRODUCTION
The biopharmaceutical classifi cation system (BCS) presents a basis for categorizing a drug based on its aqueous solubility and permeability with an eye toward drug absorption. 1 The BCS has had great impact in early development of potential therapeutics by providing signifi cant insight into the formulation of new drugs, in addition to its primary role in the waiver of in vivo bioequivalence studies for BCS class I drugs. More recently, there has been signifi cant interest in considering the BCS properties in the discovery stages of research.
The BCS guidance considers 2 primary facets of a drug ' s properties. The solubility designation is based upon the lowest solubility determined for a compound in the pH range of 1.0 to 7.5. A compound is considered highly soluble if the highest immediate-release dose is soluble in 250 mL of aqueous media in this entire pH range. Otherwise, the compound falls into the poor solubility category. It is worth noting that, while the U.S. Food and Drug Administration ' s guidance 2 is clear, there is considerable debate in the literature on whether this defi nition of high and low solubility is too conservative. 3 The alternate volume of 500 mL has been proposed as a better choice because it refl ects the average volume of the small intestines in the fasted state. There is also debate about the pH range of interest, with the range of 1.0 to 6.8 being suggested, given that a compound should be fully dissolved prior to reaching the ileum, assuming rapid dissolution. The high permeability criterion is defi ned as 90% or higher intestinal absorption. Below 90% absorption, the compound is considered to have low permeability. In practice, this is somewhat diffi cult to determine in discovery, as human data are only sparingly determined.
This report reviews the current status of computational tools in predicting the base properties of the BCS. Although we have not been truly comprehensive, we have sought to provide as complete an understanding of the status of the fi eld as possible. In addition, we provide our perspective on the progress of research into an in silico equivalent to the BCS.
SOLUBILITY PREDICTION
As solubility prediction has been the focus of several reviews over recent years, [4] [5] [6] [7] [8] [9] [10] [11] we will focus on work from only the last few years, with a particular focus on related methodologies that may positively affect solubility prediction in the future. We turn the reader ' s attention to an excellent review of solubility prediction by Delaney, 7 who discusses some of the major obstacles faced in empirical solubility modeling. 12 Most of the previous reviews point out that solubility modeling efforts have suffered from some basic concerns, such as training sets that are not druglike, unknown or high experimental error, lack of structural diversity, incorrect tautomers or structures, neglect of ionization, no consideration of salt and/or common ion issues, avoidance of crystal packing effects, and range in solubility data that is not pharmaceutically relevant. A small number of publications are starting to address many of these issues, especially the issues relating to data quality and scope, though no publication has tried to address all of them. Practically speaking, a model that addressed all of these issues Delaney 7 mentions the need for a " fi t-for-purpose " (FFP) metric to compensate for the broad range of solubilities over which most reports model performance. By presenting statistics over ranges of up to 13 orders of magnitude, the statistics often portray a rosier picture of the model's utility than is often experienced in a pharmaceutical discovery project. We are most interested in the performance of models in the key 0.1 g/mL to 250 g/mL range for discovery, which corresponds to roughly -7 to -3.5 logS in molarity for a compound with a molecular weight (MW) of ~500. When higher than this range, solubility is rarely at the forefront of issues in a discovery project. Solubility measurements below 0.1 g/mL are very diffi cult analytically, making it practically impossible to verify such predictions. In this review, we will report statistics for solubility models for compounds in this range, when possible, referring to it as the " FFP range. " When only a qualitative statement can be made based on a fi gure from the original paper, we will identify it as such.
Several manuscripts have appeared with models of varying complexity for the prediction of solubility. 4 , 8-10 , 13-36 We will discuss only a few in depth; several others are listed in Table 1 .
Bergstrom et al used carefully measured solubility data for druglike compounds to develop a series of predictive models. 28 Both general models and a series of more localized models were generated and compared. The consensus model used a combination of topological, physicochemical, and surface area descriptors and had an R 2 = 0.80. In the FFP range, the consensus was R 2 = 0.62, which is encouraging. The authors also reported predictions for the oft-used data from Huuskonen et al 38 and Jorgensen and Duffy, 39 providing a nice example of a common phenomenon in absorption, distribution, metabolism, and excretion (ADME) modeling: the lack of transferability of empirically parameterized models. The correlation for compounds in this external test set in the FFP range was a very disappointing R 2 = 0.22. To the authors ' credit, the paper contains a signifi cant discussion of the suitability of this external set compared with the training data. Much of this discussion echoes concerns raised previously. 12 , 22 Yan and Gasteiger have published several recent reports of solubility models. 22 , 25 , 29 In their initial reports, 22 , 25 the authors used the Huuskonen et al 38 data set for training but found that it was of limited applicability when the resulting models were tested by a large data set provided by Merck KGaA. In their most recent report, 29 the authors used the 
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Merck data set for training and the Huuskonen data for prediction. The outcome was quite reasonable for the Huuskonen test data, although both the correlation coeffi cient ( R 2 = 0.83 compared with R 2 = 0.92 previously, 3D neural network models) and the mean absolute error (0.66, compared with 0.49 in the earlier work) degraded substantially compared with those of the earlier report. The authors note that the Merck data set contains a more diverse collection of compounds than the Huuskonen data, which may partially explain why the model trained on the Merck data performed somewhat better in predicting the Huuskonen data than vice versa. Not enough data were given to determine the results in the FFP range, although based on the fi gures in the earlier papers, 22 , 25 the statistics for the test data in the FFP range were not as good as for the entire data set.
Two very interesting recent papers applied the HYBOT descriptors to solubility prediction of liquids 37 and solids. 36 They are both discussed in greater detail below, in the section about crystal effects on solubility prediction.
A few reports of models for the prediction of aqueous solubility of pharmaceutical salts have emerged in recent years. [40] [41] [42] [43] Parshad et al developed a model for the solubility of benzylamine salts with a combination of experimental and theoretical descriptors. 42 The best purely computational model employed the Charton steric parameter, Hansch parameters, and the MW of the salt, resulting in R 2 = 0.73 for the training data and R 2 = 0.70 for the validation data. Tantishaiyakul 41 reused the benzylamine data set to develop a computational neural network model using only calculated descriptors. The model used the number of H-bond acceptor oxygens, the total H-bond number, the clogP, the surface area, MW, and the calculated binding energy between the salt and benzylamine. The 6-2-1 network had an overall R 2 = 0.87 and a root-mean-square error (RMSe) = 0.17. An earlier report by Tantishaiyakul 40 reported a simple partial leastsquare (PLS) model for the solubility prediction for a series of diclofenac salts. Though limited in scope, these reports represent an interesting application of modeling.
To forecast the exposure of a potential drug, the entire pH range of the gastrointestinal tract must be accounted for in the prediction of aqueous solubility. [44] [45] [46] Indeed, fundamental to the BCS is the dose number, or the ratio of the dose to the amount of compound that will dissolve in 250 mL at the minimum solubility in a pH range of 1 to 8. 47 Several models have appeared that account for ionization, typically through the use of the Henderson-Hasselbach (HH) equation with predicted pK a values. Bergstrom et al 48 performed an elegant study of the appropriateness of the HH equation to 25 druglike monoprotolytic cationic compounds in divalent buffer systems. They show a range of slopes from 0.5 to 8.6 for the linear portion of the experimental pH-solubility curve, compared with the assumed value of 1 used in the HH equation. They conclude that this variability in slopes is due to a combination of low-MW aggregation and salting out effects of the phosphate counter-ion. Furthermore, they show that the range of solubility over the pH-solubility curve varies from 1.1 log units to 6.3 log units, most likely as a result of the common ion effect. In total, the HH estimated solubility at pH 6.5 deviated from the measured solubility by 10-fold on average, and up to 776-fold in the extreme.
Interestingly, Schaper et al attempted to correct their training data for the effect of ionization. 37 A relatively small portion of their training data were ionizable compounds with no reported pH information. Their assumption was that the solubility measurements were done in unbuffered solution.
To determine the pH of the solution (and, therefore, the fraction of compound un-ionized at that pH), they numerically solved a third-or fourth-order equation using an observed solubility measurement and known pK a . They then used the resulting fraction un-ionized term as a feature in their model.
The aqueous solubility of potential drugs is typically measured in a buffered salt solution, which further complicates solubility prediction. The Setschenow equation 49 describes the ratio of the solubilities of an organic solute in an aqueous salt solution versus pure water:
where S is the solubility of the solute in the aqueous salt solution, S o is the solubility in water, C salt is the molar concentration of the electrolyte, and K salt is the solute-specifi c Setschenow constant. There have been 2 recent examples of models reported to predict Setschenow constants. 50 , 51 Ni and Yalkowsky 50 demonstrate a fairly simple relationship between clogP and the Setschenow constant (K salt = 0.040 clogP + 0.114, r 2 = 0.60, n = 101, SE = 0.041). They also show that this relationship is superior to previously hypothesized links between K salt and aqueous solubility 52 or the molar volume calculated by the Le Bas method. 53 Li et al 51 generate results of similar quality using topological connectivity indices. A simplifi ed mechanistic look at Setschenow constants was among the properties investigated by the " Mercedes Benz " model of water. 54 The direct application of any of these approaches in the in silico prediction of aqueous solubility is still lacking.
Yet another factor in solubility prediction that is often ignored is the role of the crystal form of a druglike solute (an early notable exception is that of Abraham and Le 55 ). An excellent recent review discusses the importance of solidstate properties on a range of developability considerations in drug discovery and development. 56 Most interesting out of this review, with respect to solubility, is the relative rarity of large solubility differences among polymorphs. Indeed, the authors state that the " solubility difference between different polymorphs is typically less than 10 times " (p.323). Pudipeddi and Serajuddin 57 go further, providing data showing that the ratio is typically less than 2. Contrasting this, however, is the extreme difference in solubility often observed between amorphous material and crystalline material. 56 In aggregate, these data could lead to the alluring possibility that, while the ability to identify the most stable crystal lattice may not be necessary, the incorporation of some realistic measure of crystal packing is crucial to practical solubility prediction.
Conversely, Nielsen et al 58 attempted to quantitatively link aspects of crystal packing to solubility for a series of N-alkyl bupivacaine salts. They did see a trend of decreasing solubility with increasing crystal lattice density. However, their analysis was frustrated by unpredictable changes in packing modes due to anionic counter-ions and the alkyl substituent. They conclude that reliable lattice energy calculations are required for deriving relationships between solubility and solid-state characteristics, even for a series of closely related analogs. This opinion is supported by Romero and Rhodes, who fi nd that even quantifying the impact of crystals of different enantiomers on solubility is nontrivial. 59 Probably the best-known solubility model that includes crystal forces is the general solubility equation (GSE) popularized by Yalkowsky 60 :
where S o is the intrinsic aqueous solubility in the units of moles/L, logP is the octanol-water partition coeffi cient, and MP is the melting point in °C. Derived from a theoretical basis with no fi t parameters, the GSE is based on a few simple assumptions, including the applicability of Walden's rule (entropy of melting) and the fact that organic neutral liquids are completely miscible with octanol. Still, the GSE performs admirably in prediction for simple organics. The requirement of a measured melting point has greatly limited the use of the GSE within the pharmaceutical industry, as melting point measurements are no longer routine in modern medicinal chemistry. Not surprisingly, several reports relating to the prediction of melting point from structure have emerged in recent years. 10 , 61-65 We will not review melting point prediction in depth here; instead, we refer the reader to the fairly recent perspective by Katritzky et al. 66 More recently, Yalkowsky has derived new parameters for predicting the entropy of melting, which presumably could be used in the GSE to remove the assumption of the applicability of Walden's rule. 63 Bergstrom and coworkers 61 generated a consensus model using 277 diverse drugs for melting point prediction that focuses on descriptors of polarity and molecular fl exibility. The RMSe of the validation data was 44.6°C. Karthikeyan et al used 4173 compounds to develop a computational neural network model of melting point. 64 The best resulting model employed 26 2-dimensional descriptors in a 26-12-1 neural network, resulting in R 2 = 0.66, with RMSe ranging from 41.4 to 49.3°C depending on which external validation set was used.
In 2 papers Raevsky and colleagues build on the GSE by deconvoluting the logP component into separate descriptors. 36 , 37 Using a collection of liquid chemicals and drugs, 37 they demonstrate that descriptors previously identifi ed [67] [68] [69] [70] as being relevant for logP prediction perform admirably in the GSE in place of the logP term. This is an interesting result, as hydrogen bond donor strength was not an important descriptor for logP prediction but appears critical for modeling solubility. By adding H-bond donor strength to their model, they improve the solubility prediction signifi cantly.
In the follow-up paper that considers solid chemicals and drugs, 36 the authors apply the GSE to 1063 neutral solidstate compounds with known melting point. The statistical performance ( R 2 = 0.85, RMSe = 0.81) was substantially less impressive than for previous data sets that included a large number of liquid-state compounds. 71 Predictions were more than a log unit off the observed values for ~19% of the compounds. Nonetheless, in our opinion this result (based on experimentally determined melting point and logP) is more than competitive with most external tests of purely in silico models reported in the literature. Based on a qualitative view of the fi gure, the predictions in the FFP range were worse than those for the data set as a whole. Of the 26 outliers noted for the entire 13 orders of magnitude, 12 fell in the 3.5 log units designated here as the FFP range.
The authors then take a novel approach to a computational model of the solubility of solids. They implicitly capture the crystal lattice energy using the observed solubility of several highly similar compounds with an adjustment based on the differences in the physicochemical descriptors identifi ed as important for predicting the solubility of liquids. 36 The resulting model performance is very competitive with those obtained for the GSE, but without the requirement for a measured melting point. Roughly 7 of the 14 outliers in this model fall in the FFP range, based on a plot in the paper. Based on the fi gures in the paper, the fi t seems better in this range for the computational model than for the experimentally based GSE.
Several methods [72] [73] [74] [75] [76] [77] [78] [79] [80] for predicting crystal lattices or quantifying lattice energy, with possible use in solubility prediction, are on the horizon. We particularly highlight the excellent recent review by Datta and Grant, 77 who discuss in comfortable detail recent efforts to predict crystal structures of druglike compounds. The molecular dynamics method proposed by Gavezzotti 78 to assess the relative stability of crystal lattices is particularly appealing, although diffi cult to implement as a fully computational method in E31 practice. In general, these approaches hold great promise but, due to their complexity and predictive limitations, are not yet practical solutions for a general treatment of crystal packing limited solubility prediction.
In summary, substantial research has been underway in predicting the aqueous solubility of druglike compounds. Of particular note is the increased awareness of the many confounding aspects of solubility that must be considered for a model to yield highly accurate predictions. We expect that in the coming years more sophisticated models will emerge that begin to more tightly integrate measures of crystal packing, salt effects, and ionization alongside solvation considerations.
ABSORPTION MODELING

Modeling of P-Glycoprotein Substrates and Inhibitors
P-glycoprotein (Pgp), which belongs to the adenosine triphosphate binding cassette transporter family, is found in all cells in every species. The effect of Pgp-mediated drug effl ux limits intestinal absorption and oral bioavailability of drugs. Because of this critical role in oral absorption and bioavailability, extensive research has been conducted to uncover the molecular features required for the substrates and/or inhibitors of Pgp transporter. Such models are expected to play an important role in early drug discovery and help reduce the attrition rate in later-stage drug development.
In recent years there have been many research articles that examined the molecular determinants of Pgp substrates and/ or inhibitors. Both qualitative and quantitative molecular models have been developed to offer insights into the molecular mechanisms as well as to provide predictive tools. Some selected modeling work is listed in Table 2 .
In 1998 Pajeva and Wiese 81 published their work on comparative molecular fi eld analysis (CoMFA) studies of phenothiazines. Later, they conducted pharmacophore modeling research of drugs involved in Pgp multidrug resistance using the genetic algorithm similarity program (GASP) pharmacophore modeling tool. 82 In a widely cited study, Seelig identifi ed 2 recognition elements for Pgp that were composed of hydrogen bond acceptors with distinct spatial arrangements. 90 Seelig referred to 2 hydrogen bond acceptors separated by ~2.5 Å as a Type I pattern; Type II patterns are formed by 2 hydrogen bond acceptors separated by ~4.6 Å, or 3 hydrogen bond acceptors separated by ~2.5 Å with a 4.6 Å separation of the outer 2 acceptor groups.
In 2002, Ekins et al reported their studies on both Pgp substrates and inhibitors using the catalyst pharmacophore modeling method. 83 , 91 Although their work has not provided detailed predictive models tested by extensive external compounds, they seem to have provided some molecular insights consistent with experimental observations. Penzotti et al described their work on classifi cation models using a special pharmacophore ensemble approach to classify Pgp substrates with an overall accuracy of 63%. 84 In addition to classifi cation models, this method revealed the molecular pharmacophores that underlie the interaction between Pgp substrates and the protein.
In the past 2 to 3 years, more work has been published concentrating on applying machine learning methods and descriptor-based quantitative structure-property relationship (QSPR) methods. Xue et al used support vector machine (SVM) to study 201 compounds, including 116 Pgp substrates and 85 nonsubstrates. 85 This method gave a prediction accuracy of at least 81.2% for Pgp substrates. The prediction accuracy for nonsubstrates was 79.2% using a cross-validation. A data set of 57 fl avonoid Pgp inhibitors was studied using a Bayesian-regularized neural network in which Molconn-Z and clogP descriptors were used. 86 Wang et al also used Kohonen self-organizing maps to develop a classifi cation model to discriminate substrates and inhibitors with an average accuracy of 82.3%. 87 The data set has 206 chemicals: 96 substrates, 78 inhibitors, and 32 overlapping compounds. Although these models may not have practical utility because of the nature of the data set collected from the literature, they do represent some new development in applying machine learning methods to the study of Pgp substrates/inhibitors classifi cation.
Two recent publications are especially interesting from a practical standpoint. Gombar et al published their work using what they called " information-rich descriptors " and linear discriminate analysis. 88 They analyzed a set of 95 compounds, including GlaxoSmithKline proprietary and known drug molecules. They paid special attention to the data consistency with unifi ed experimental protocol. In addition to a regular QSPR classifi cation model, they proposed a simple rule for Pgp substrates. Another recent work described a novel approach to performing alignmentindependent 3D quantitative structure-activity relationship (QSAR). 89 This method not only afforded statistically tested predictive models but also revealed potential pharmacophore requirements. In the following text, we provide some more detailed discussion of these 2 publications as well as that published by Penzotti et al. 84 One of the early efforts in gathering and modeling a large set of diverse Pgp compounds was published by Penzotti et al. 84 They assembled a data set of 195 compounds from the literature. In the study, they used a holdout set of ~25% of the compounds selected randomly from the 195 compounds. The test set contained 32 Pgp substrates and 19 nonsubstrates. The remaining 144 compounds, including 76 substrates and 68 nonsubstrates, were used as the training data set to derive the computational model.
One interesting fact about their method is that they characterized the chemical similarity using the Daylight Tanimoto similarity measure. The average pairwise Daylight Tanimoto similarity of all 195 compounds is 0.18. The training set and the test set compounds also have comparable pairwise similarities. This is an important metric because it indicates that their method may be used to predict compounds from different chemical classes. The classifi cation rates of the fi nal pharmacophore ensemble model are 80% and 63% for the training and test sets, respectively.
In addition to the classifi cation model, which can be used as a virtual library fi lter, the authors derived molecular pharmacophores. Contained in the signifi cant pharmacophores are examples of the Type I and Type II patterns composed of hydrogen bond acceptors described by Seelig. 90 This indicates that their method can successfully provide molecular models in addition to classifi cation models. In 2005 Cianchetta et al described another exciting effort. 89 They derived a pharmacophore hypothesis based on a set of 129 compounds (100 Sanofi -Aventis compounds and 29 publicly available compounds). The data set was divided into 4 classes based on compound activity values. They proposed a novel set of descriptors based on GRID calculated interaction fi elds followed by modifi ed autocorrelation calculation. This generated 940 descriptors similar to pharmacophore keys. The results included both predictive models and pharmacophore descriptions. The models using VolSurf descriptors achieved training set R 2 = 0.72 and Q 2 = 0.52; for combined pharmacophore descriptors and 94 VolSurf descriptors, the training R 2 = 0.80 and Q 2 = 0.72. The models derived using only pharmacophore descriptors after some preselection gave a training R 2 = 0.82 and Q 2 > 0.72. The pharmacophore hypothesis includes 2 hydrophobic groups 16.5 Å apart and 2 hydrogen bond acceptor groups 11.5 Å apart.
To develop reliable models for Pgp substrates/inhibitors identifi cation, future work should attend more to data 
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consistency. Model validation using a true holdout set should always be attempted. In addition to traditional QSPR models, which can be useful in virtual screening and database search exercises, more interpretable models or rules can be very useful for medicinal chemists to consider in the lead optimization work. These are represented by Gombar ' s work and Cianchetta ' s work, reviewed above. Only when we achieve this can such tools have a broad impact on lead optimization projects in assisting chemists in morphing the chemical series at hand to increase potency and decrease Pgp liability.
Modeling of Intestinal Permeability
Intestinal drug permeability, together with aqueous solubility, is one of the most important factors infl uencing drug absorption. In recent years, various in vitro permeability models have been developed to help predict oral drug absorption and bioavailability. These include Caco-2, Madin-Darby canine kidney (MDCK), and 2/4/A1 cell culture models, as well as the parallel artifi cial membrane permeability assay (PAMPA) and immobilized artifi cial membrane (IAM) and physicochemical models. While the former can refl ect both transcellular and paracellular routes of permeability, as well as active transport to some degree, the latter models mostly mimic the transcellular route of drug permeability. 92 As the in vitro models continue to develop and mature in terms of their throughput and quality, computational methods that can correlate chemical structures and their experiment permeability measurements are highly desirable. These in silico models, when carefully developed and rigorously validated, have the potential to be used in early screening set or library design. They can also play a role in lead optimization and preclinical candidate selection. Several computational models for permeability are shown in Table 3 . Recently, Bergstrom reviewed the application of polar surface area (PSA) as a descriptor to model permeability and solubility data. 93 Malkia et al looked at various physicochemical factors underlying the permeation process, in vitro experiment models as well as in silico modeling of permeability. 94 These reviews covered mostly articles published prior to 2002. We will look at some more recent work on this topic.
Kulkarni et al analyzed 38 compounds and tested the model using 8 additional compounds. 95 They created a model monolayer to represent the membrane structure. They calculated both intramolecular properties and intermolecular properties, which characterized the interaction with the membrane as well as solute dissolution and solvation. A series of models were developed using 1 to 6 terms using multiple linear regression (MLR). Most models gave R 2 > 0.8 and Q 2 > 0.70. This method also provided some mechanistic interpretation of the model. That is, the Caco-2 permeability depended on several factors: solubility, drugmembrane binding, and conformational fl exibility.
Yamashita et al developed a model of Caco-2 permeability using genetic algorithm with partial least squares (GA-PLS). 96 Data for 73 compounds were collected from the literature. Molconn-Z descriptors were employed. The model achieved R 2 = 0.886 for the entire data set and a predictive R 2 = 0.825. In a related work, they also developed a new concept -the latent membrane permeability conceptto model permeability data from different sources. 97 Eightyone compounds were analyzed based on this concept using an iterative calculation method. It analyzed the Caco-2 permeability from different sources simultaneously, assuming that all the data sets share a hidden, common relationship between their permeability and their physicochemical properties. The model achieved R 2 ranging from 0.75 to 0.88.
Using a combination of molecular orbital (MO)-calculation and neural network analysis, Fujiwara et al developed a model of Caco-2 permeability. 98 The data set had 87 compounds. They used dipole moment, polarizability, sum of charges on nitrogen and oxygen atoms, and so on. A feedforward back-propagation neural network with a confi guration of 5-4-1 was developed. The predictive root mean square error was 0.507 in cross-validation.
Marrero et al developed a new set of topological descriptors called quadratic indices. 99 They applied these descriptors to analyze Caco-2 permeability data for 33 compounds. The model could distinguish the high-absorption compounds from those with moderate-to-poor absorption. A global classifi cation rate was 87.87% using LDA. In a test experiment, they used the model to assess 18 compounds; the classifi cation rates were 80.00% and 94.44% for the moderateto-poor and high-absorption groups, respectively.
Hou et al 100 analyzed a data set of 77 compounds with Caco-2 permeability data collected from literature sources. The descriptors included logD at pH = 7.4, highly charged PSA (HCPSA), and radius of gyration (rgyr), representing the shape and volume of the compounds. They found that logD had the largest impact on diffusion through Caco-2. The comparison among HCPSA, PSA, and topological PSA (TPSA) demonstrates the importance of the highly charged atoms to the interactions between Caco-2 cells and drugs.
The results also indicate that lipophilicity, H-bonding, bulk properties, and molecular fl exibility can improve the correlation. The model statistics are n = 77, R 2 = 0.82, and Q 2 = 0.79. The authors also validated the model using an external set of 23 compounds and achieved similar predictions.
Fujikawa et al developed QSPR models for data based on PAMPA assay. 101 Descriptors included logP, |pK a -pH| and the surface areas occupied by the hydrogen-bond acceptor (SAHA) and donor atoms (SAHB). The data set had 35
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compounds. The authors used the PLS correlation method. The model yielded R 2 = 0.84 and Q 2 = 0.79. In another data set that had 57 compounds, the authors obtained a model with R 2 = 0.78 and Q 2 = 0.74. They also demonstrated that PAMPA and Caco-2 data were well correlated for this data set (n = 27; R 2 = 0.81; Q 2 = 0.78). Based on these results, they suggested a procedure by which one could in theory predict the oral absorption of compounds.
In a recent publication, Refsgaard et al developed in silico models of membrane permeability based on the largest selfconsistent data set published so far. 102 They analyzed 712 compounds (380 nonpermeable, 332 permeable) to develop a 2-class classifi cation model. The permeability data were binned into 2 classes based on apparent permeability: those below 4 × 10 − 6 cm/s were classifi ed as low permeability, and those with 4 × 10 − 6 cm/s or higher were classifi ed as high permeability. Nine molecular descriptors were calculated for each compound. A 5-descriptor Near Neighbor model (number of fl exible bonds, number of hydrogen bond acceptors and donors, and molecular surface area and PSA) was built. The model was tested using an external set of 112 compounds. The misclassifi cation rate was 15%, and no compounds were falsely predicted in the nonpermeable class.
Most of the published work is based on small sets of permeability data (<100 compounds) that are collected from literature sources. Since the validity of any model depends on the data set used, a large and self-consistent data set is required for the development of global models with general applicability. It is highly desirable to develop the models using data generated from the same lab using the same protocols. For example, Artursson et al compared 4 calibration curves relating the fraction absorbed in human and Caco-2 permeability. They demonstrated that the curves were shifted relative to one another by ~0.25 to 1.75 log permeability units. 103 Local models may solve this problem by building compound class-specifi c models using, again, selfconsistent data. It is exciting to see such work as Refsgaard et al ' s publication, 102 which was based on a large set of >700 compounds with data from the same laboratory.
Model validation is another critically important step in building robust QSPR models. Ideally, one should report results based on the training set, the cross-validation set, and an external data set to increase the users ' confi dence level. Consistent reporting of model statistics is highly desirable so that readers can objectively evaluate the model quality and applicability in a real-life drug discovery setting. For example, for quantitative QSPR models, one may want to report the (training set) R 2 , leave-one-out (leavesome-out) R 2 or Q 2 , external holdout R 2 , and RMSe between the experimental values and the predicted values. For classifi cation models, a " confusion matrix " may need to be published in addition to an overall classifi cation rate, which may be biased by extreme values. The confusion matrix also provides information on false-positive and falsenegative in addition to correct classifi cations.
We hope that more permeability modeling work will be based on larger self-consistent data sets and will adopt rigorous validation procedures, as discussed above. Only by doing so can we move the fi eld forward from the proof-ofconcept stage to having real-life impact in drug discovery setting. 
Modeling of Bioavailability and Fraction Dose Absorbed
Bioavailability is used to describe the fraction of an administered drug that reaches the systemic circulation and its site of action. Oral bioavailability is the result of a complex series of events: chemical and enzymatic stability, solubility and dissolution, and intestinal permeability. Because of incomplete absorption and fi rst pass metabolism and other stability factors, bioavailability is usually <100%. To lower the attrition rate of drug development, we need to develop robust and accurate in silico models that can predict and prioritize compounds before they are synthesized or moved forward to preclinical and clinical development.
There are several approaches to the development of computational models for bioavailability and fraction dose absorbed. Rules derived from statistical analysis of known oral drugs have been popularized by Lipinski et al ' s seminal work. 104 More predictive mechanistic models are appearing in the literature. [105] [106] [107] QSPR methods that employ molecular descriptors and machine learning techniques continue to develop. Here we review some of the work in this area, most of which was published after 2002.
Statistically Derived Rules
Since Lipinski et al ' s infl uential work 104 on the analysis of orally active drugs to derive the widely publicized rule (ie, the " rule of 5 " ), several groups have studied this issue, trying to uncover other factors that may also be important for oral bioavailability. Veber et al described their analysis of oral bioavailability data in rats for over 1100 drug candidates. 108 A number of these rules and alerts are shown in Table 4 . They found that reduced molecular fl exibility and low PSA (or total hydrogen bond counts) are important predictors of good oral bioavailability. They suggested that compounds that meet only the 2 criteria of (1) 10 or fewer rotatable bonds and (2) PSA equal to or less than 140 A 2 (or 12 or fewer total H-bonds) will have a high probability of good oral bioavailability in the rat.
Lu et al studied the relationship of rotatable bond count and PSA with oral bioavailability in rats and compared their results with Veber et al ' s. 109 They examined 434 Pharmacia compounds. Although the general trend of Veber ' s fi nding was still seen, the resulting correlations depended on the calculation method and the therapeutic class of the compounds. Thus, Lu et al suggested that any generalization must be used with caution. Later, Vieth et al analyzed 1729 marketed drugs and found that oral drugs tended to be lighter and had fewer H-bond donors, acceptors, and rotatable bonds than did drugs with other routes of administration, especially when oral and injectable drugs were compared. 110 Again, this observation was in general consistent with Veber et al ' s fi nding. However, they also cautioned that these were general statistical observations and might not be applicable for a particular drug or a class of drugs.
Recently, Martin developed " a bioavailability score " (ABS), a method to estimate the bioavailability of potential drugs. 111 This work was based on a diverse set of 553 compounds (99 different rings and 180 different side chains) with rat bioavailability data. They further used the ABS to examine the human data for 449 compounds. The most interesting discovery was that the rule of 5 could identify poorly bioavailable compounds that are neutral and positively charged but could not predict anionic compounds. On the other hand, the PSA rule worked for anionic compounds, not for neutral and cationic ones. When they separated the anionic compounds from the neutral and cationic compounds, a set of interesting rules emerged, from which the ABS can be estimated.
The ABS indicates the probability that a compound will have >10% bioavailability in rat or measurable Caco-2 permeability. For example, for anions, the ABS is 0.11 if PSA >150 Å 2 , the ABS is 0.56 if PSA is ≥ 75 and ≤ 150 Å 2 , and the ABS is 0.85 if PSA is <75 Å 2 . For cationic and neutral compounds, the ABS is 0.55 if it passes the rule of 5 and 0.17 if it fails the rule of 5.
Mechanism-Based Pharmacokinetics Models
One advantage of mechanism-based pharmacokinetics (PK) models is that they can provide mechanistic details and hypotheses that may guide the chemist ' s work in optimizing the PK properties of compounds. In the past couple of years, a few published articles have indicated the potential predictive power of these models as well.
Usansky and Sinko developed an absorption-disposition model that predicted bioavailability values (%F) well for both highly and poorly absorbed drugs. 106 For 49 of the 51 compounds in the study, the residuals between predicted and experimental %F values ranged from -17% to 22%. This model offers a quantitative approach for predicting human oral absorption from in vitro permeability and perhaps from computationally predicted permeability as well.
Obata et al developed a theoretical passive absorption model (TPAM). 107 It used logD at pH 6.0, intrinsic logP, pK a , and MW that were calculated from the chemical structures. Willmann et al developed a physiologically based model. 105 The model can be used to study the dependency of the fraction dose absorbed on the 2 main physicochemical parameters (the intestinal permeability and the solubility) as well as physiological parameters such as the gastric emptying time and the intestinal transit time. The model parameters were optimized using 126 compounds with known %F values. The model was used to predict the human %F values with permeability-limited absorption; the cross-validation RMSe was 7% for passively absorbed compounds. This model required experimentally measured permeability data. However, it is conceivable that well-validated computational data may also be applicable.
QSPR Approaches to Modeling Bioavailability
In the past 3 years, we have seen various efforts to model oral bioavailability using the descriptor-based QSPR approaches. Both linear and nonlinear learning methods have been applied in either quantitative modeling or classifi cation modeling of bioavailability. 115 analyzed 1000 druglike compounds with experimental human intestinal absorption values using recursive partitioning. They were able to achieve 15% false-positives and 3% false-negatives classifi cation rates. Klopman et al 116 developed a model based on a modifi ed group contribution method using the computer automated structure evaluation (CASE) program. The data set contained 417 compounds. The model was able to predict the percentage of drug absorbed with an R 2 of 0.79 and a standard deviation of 12.3% for the compounds from the training set. The standard deviation for an external test set for 50 drugs was 12.3%.
In an earlier work, Yoshida and Topliss 117 analyzed 232 compounds with human bioavailability data. They discovered that acids generally had better bioavailability than bases, with neutral compounds in between. One interesting idea that came out of this observation was the formulation of a new parameter, the differential logD (logD6.5-logD7.4), which contributed signifi cantly to the bioavailability. The model had a correct classifi cation rate of 71%, a cross-validation rate of 67%, and a validation rate of 60% for 40 compounds. Similarly, Andrews et al analyzed 591 compounds with human oral bioavailability. 118 They used substructure count descriptors, recursive partitioning, and stepwise regression. The model achieved predictions with an RMSe of ~18%.
All 3 types of approaches to the modeling of bioavailability data have their pros and cons. The rules/alerts often provide intuitive and easy ways to think about the issues and help guide the chemist ' s efforts in designing new molecules. However, these rules/alerts do not often perform as well as the well-validated QSPR models. Thus, QSPR models can play a critically important role in virtual screening, compound collection, or library design work. The mechanismbased PK models can provide mechanistic insights and help decipher the components of the oral absorption process. Thus, such models often play an important role in the lead optimization and candidate selection process. It is highly likely that these in silico models will become more robust and accurate in the future as more self-consistent data of bioavailability become available. Until then, researchers have to use these rules/alerts/models with caution and should always validate these models with known experimental data before making any critical decisions.
CONCLUSION
We have attempted to provide a summary of the progress in computational modeling of aqueous solubility, Pgp effl ux, and absorption. While signifi cant effort continues in modeling these critical components of the BCS, much work remains in making predictions reliable and thus of impact to discovery. During our survey of the literature, very few applications of either solubility models or permeability models in the prospective design of new compounds were uncovered, with the exception of the use of clogP or PSA. While it is impossible to identify what has caused this dearth of application, we speculate that the primary reasons are low prediction reliability and the lack of model interpretability that would provide guidance for chemical synthesis.
Our personal experience would imply that striving for high prediction accuracy, while scientifi cally appealing, is often at odds with assembling a model that will appeal to chemists. A better practice is to present interpretable models that can provide several testable hypotheses for advancing a chemical series. Models of this sort are still absent from the literature.
To this point, a reliable in silico analog to the BCS is still lacking, although great progress has been made at understanding the underlying properties. With typical prediction accuracies of 1 to 2 orders of magnitude in solubility, and comparably high errors of prediction for absorption-related parameters, trustworthy computational estimates of the maximum absorbable dose still appear out of reach generally. Nonetheless, as a tool alongside in vitro assays for early parameterization of physiologically based pharmacokinetic (PBPK) models, or as a starting point for refi ned models of a constrained series of chemical analogs, solubility and absorption models play an increasingly important role in drug discovery.
